MPP Gives 18 December Deadline For Dolutegravir Sublicense Applications
Follows November Licensing Agreement For Four Countries
The Medicines Patent Pool is giving interested parties until 18 December to submit license applications for the HIV treatment dolutegravir in four middle-income countries, following announcement of the agreement last month.
You may also be interested in...
A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.
The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.
The Medicines Patent Pool has announced that the first shipments of dolutegravir under a fresh agreement covering upper-middle-income countries have reached Azerbaijan and Belarus.